Roche’s Alecensa kept people with a specific lung cancer alive longer without their disease progressing than Xalkori as it seeks to move in on Pfizer’s share of early treatment of the disease.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
Takeda Pharmaceutical completed enrollment for a 20,000-subject dengue vaccine trial, the largest clinical study in the company’s history.
A common antibiotic called doxycycline can disrupt the formation of negative thoughts and fears in the brain and may prove useful in treating or preventing post traumatic stress disorder (PTSD), according to research by British and Swiss scientists.
Patients with advanced melanoma who received Bristol-Myers Squibb’s immunotherapies Opdivo and Yervoy had improved overall survival versus those on Yervoy alone.
Vertex Pharmaceuticals Inc. said its Kalydeco cystic fibrosis treatment given with an experimental drug demonstrated significant improvements in lung function in a pair of late-stage trials the company plans to use to seek approval of the combination therapy.
Foamix Pharmaceuticals Ltd. said its experimental acne treatment failed to meet one of two main goals in a late-stage study, pushing its shares down about 42 percent.
Shares of Ultragenyx Pharmaceuticals were down after the company announced its Phase II drug UX007 to treat seizures failed to meet trial goals.
GlaxoSmithKline and Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank to hunt for new clues linking genes and disease.
Novartis’ heart failure drug serelaxin flopped in a late-stage trial by not cutting cardiovascular death or slowing disease progression, marking the likely demise of a drug hopeful the Swiss firm had promoted as a potential blockbuster.
Eli Lilly and Co.’s combination of its experimental breast cancer drug abemaciclib and another widely used treatment slowed disease progression.
Nektar Therapeutics said its experimental opioid succeeded in a key late-stage study.
Catalyst Pharmaceuticals Inc.’s experimental drug to treat patients with a severe form of myasthenia gravis, a rare neuromuscular disease, met the main goals of a study.
DynPort’s clinical stage recombinant Yersinia pestis rF1V plague vaccine to benefit from FDA Orphan Drug Designation FALLS CHURCH, Va., March 8, 2017 /PRNewswire/ — CSRA Inc. (NYSE: CSRA) today announced that a plague vaccine being developed by its subsidiary, DynPort Vaccine Company LLC (DVC), was granted Orphan Drug Designation from the U.S. Food and Drug Administration […]
Nearly two decades ago, the promise of precision medicine began making its mark on the pages of medical journals – along with speculation that “therapy with the right drug at the right dose in the right patient” – would define the future of medical treatment.
Sanofi and Regeneron said results from a one-year test of Dupixent aimed at adults with eczema or moderate-to-severe atopic dermatitis had been positive.
Study data showed patients treated with guselkumab experienced significantly greater improvements compared with the anti-TNF-alpha treatment Humira.
Chi-Med’s fruquintinib met all main endpoints in a Phase III trial as a third-line treatment in patients with locally advanced or metastatic colorectal cancer.
PTC Therapeutics Inc. said it would stop developing its cystic fibrosis drug after it failed to meet the main goal of a late-stage study.
Roche’s bid to shield its lucrative oncology franchise from generics got a lift from a trial showing a new drug cocktail kept breast cancer patients alive longer.
Kite Pharma Inc.’s experimental CAR T-cell therapy was highly effective in treating aggressive non-Hodgkin’s lymphoma, meeting the main goal of a key study.